Table 1.
Subject demographics and baseline clinical characteristics.
| Variables | Eyes with Focal LC Defect (41 eyes, 41 patients) | Eyes without Focal LC Defect (41 eyes, 41 patients) | P-value |
|---|---|---|---|
| Age (years) | 73.4±14.0 (36 to 94) | 72.0±9.5 (51 to 89) | 0.235* |
| Gender (male/female) | 20/21 | 24/17 | 0.507† |
| SE (D) | −0.95±2.2 (−8.4 to 2.3) | −0.94±1.7 (−5.1 to 2.9) | 0.568* |
| CCT (μm) | 529.1±42.3 (460.3 to 606.0) | 532.3±40.7 (425.3 to 619.0) | 0.739‡ |
| Ethnicity (ASD/ED/AFD) | 9/24/8 | 3/29/9 | 0.171† |
| Self-reported diabetes, n (%) | 6 (14.6 %) | 4 (9.8 %) | 0.736† |
| Self-reported hypertension, n (%) | 22 (53.7 %) | 19 (46.3 %) | 0.659† |
| Antihypertensive medication, n (%) | 17 (41.5 %) | 16 (39.0 %) | 1.000† |
| Diabetes medication, n (%) | 5 (12.2 %) | 3 (7.3 %) | 0.710† |
| Number of topical glaucoma medications, n (%) | |||
| 0 | 1 (2.4 %) | 4 (9.8 %) | 0.246† |
| 1 | 16 (39.0 %) | 11 (26.8 %) | |
| >1 | 24 (58.5 %) | 26 (63.4 %) | |
| Topical medications, n | |||
| Prostaglandin analogues | 31 | 30 | 0.990† |
| Beta-antagonists | 16 | 17 | |
| Carbonic anhydrase inhibitors | 6 | 7 | |
| Alpha-1-antagonists | 20 | 20 | |
| IOP (mmHg) | 13.5±5.7 (4 to 30) | 13.1±4.4 (4 to 26) | 0.787‡ |
| SBP (mmHg) | 127.1±14.2 (92 to 162) | 121.9±12.8 (98 to 151) | 0.083‡ |
| DBP (mmHg) | 77.5±11.3 (51 to 108) | 75.9±9.2 (51 to 100) | 0.474‡ |
| MOPP (mmHg) | 54.7±8.6 (35.1 to 75.8) | 52.5±6.2 (39.3 to 66.7) | 0.197‡ |
| Pulse rate (bpm) | 67.9±12.4 (46 to 108) | 66.0±11.4 (41 to 85) | 0.767* |
| Disc hemorrhage, n (%) | 4 (9.8 %) | 7 (17.1 %) | 0.517† |
| VF MD (dB) | −6.60±6.02 (−25.87 to −0.41) | −5.82±6.08 (−26.24 to −0.30) | 0.252* |
| VF PSD (dB) | 6.60±3.96 (1.71 to 14.57) | 5.63±3.69 (1.82 to 14.37) | 0.286* |
| Disc area (mm2) | 2.2±0.4 (1.4 to 3.2) | 2.0±0.53 (0.93 to 3.0) | 0.156‡ |
| RNFL thickness | |||
| Global area (μm) | 72.2±10.2 (51.9 to 98.9) | 73.7±14.1 (41.5 to 110.7) | 0.576‡ |
| Upper temporal (μm) | 60.4±14.7 (31.6 to 93.8) | 60.0±15.4 (31.7 to 86.7) | 0.895‡ |
| Upper nasal (μm) | 64.6±12.8 (43.2 to 98.7) | 62.9±13.1 (32.0 to 105.5) | 0.558‡ |
| Lower nasal (μm) | 61.3±11.2 (36.9 to 88.1) | 59.8±11.1 (35.8 to 81.6) | 0.554‡ |
| Lower temporal (μm) | 53.6±9.7 (35.7 to 84.8) | 55.0±14.4 (28.1 to 103.6) | 0.608‡ |
| Superotemporal (μm) | 95.2±21.0 (56.0 to 136.3) | 97.0±23.3 (50.2 to 144.1) | 0.714‡ |
| Superonasal (μm) | 81.9±14.7 (48.2 to 113.9) | 81.9±20.8 (52.3 to 138.0) | 0.901‡ |
| Inferonasal (μm) | 80.3±20.4 (48.8 to 139.3) | 84.7±23.1 (40.7 to 135.7) | 0.366 ‡ |
| Inferotemporal (μm) | 80.6±21.4 (50.9 to 127.9) | 88.1±25.7 (46.6 to 142.6) | 0.154* |
Continuous variables are shown in mean ± standard deviation (range).
*
The comparison was performed by using Mann-Whitney test.
†
The comparison was performed by using Chi-squared test.
‡
The comparison was performed by using independent samples t-test.
SE = spherical equivalent; CCT = central corneal thickness; ASD = Asian descent; ED = European descent; AFD = African descent; IOP = intraocular pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; MOPP = mean ocular perfusion pressure; VF MD = visual field mean deviation; VF PSD = visual field pattern standard deviation; RNFL = retinal nerve fiber layer.